论文部分内容阅读
AIM: To investigate the effect of oral solifenacin succinate, tolterodine-L-tartarate and oxybutinin hydrochloride(HCl) on accommodation amplitude.·METHODS: Female overactive bladder syndrome(OAB)patients who were planned to use oral anticholinergics,patients that uses solifenacin succinate 5 mg(Group I,n =25), tolterodine-L-tartarate 4 mg(Group II, n =25),and oxybutinin HCl 5 mg b.i.d.(Group III, n =25) and age matched healthy female subjects(Group IV, n =25) were recruited and complete ophthalmological examination and accommodation amplitude assessment were done at baseline and 4wk after initiation of treatment.·RESULTS: The mean age of 100 consecutive female subjects was 51.6 ±5.7(40-60)y and there were no statistically significant difference with regard to the mean age(P =0.107) and baseline accommodation amplitude(P =0.148) between study groups. All treatment groups showed a significant decrease in accommodation amplitude following a 4-week course of anticholinergic treatment(P =0.008 in Group I, P =0.002 in Group II, P =0.001 in Group III), but there was no statistically significant difference in Group IV(P =0.065).·CONCLUSION: A 4-week course of oral anticholinergic treatment have statistically significant effect on accommodation amplitude. Clinicians should avoid both overestimating this result, as this would unnecessarily restrict therapeutic possibilities, and also underestimating it which may lead to drug intolerance.
AIM: To investigate the effect of oral solifenacin succinate, tolterodine-L-tartarate and oxybutinin hydrochloride (HCl) on accommodation amplitude. METHODS: Female overactive bladder syndrome (OAB) patients who were planned to use oral anticholinergics, patients that uses solifenacin succinate 5 mg (Group I, n = 25), tolterodine-L-tartarate 4 mg (Group II, n = 25), and oxybutinin HCl 5 mg bid RESULTS: The mean age of 100 consecutive female subjects was 51.6 ± 5.7 (40-60) y and there were no significant significant difference with regard to the mean age (P = 0.107) and baseline accommodation amplitude (P = 0.148) between study groups. All treatment groups showed a significant decrease in accommodation amplitude following a 4-week course of anticholinergic treatment = 0.008 in Group I, P = 0.002 in Group II, P = 0.001 in Group III), but there was no significant significant difference in Group IV (P = 0.065). CONCLUSION: A 4-week course of oral anticholinergic treatment statistically significant effect on accommodation amplitude. Clinicians should avoid both overestimating this result, as this this would probably not restrict therapeutic possibilities, and also underestimating it which may lead to drug intolerance.